NCT02433795 2026-04-22
Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
Seoul National University Hospital
Phase 2 Completed
Clinical Trials
8 trialsNCT05100862 2026-04-22
MAHOGANY
BeOne Medicines
Phase 3 Recruiting
NCT04799275 2026-04-14
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI)
Phase 2/3 Suspended
NCT04840602 2026-04-13
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06149286 2026-04-13
OLYMPIA-5
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT04433156 2026-04-09
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
Henan Cancer Hospital
Phase 2 Completed
NCT03697512 2026-04-08
MALIBU
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Active not recruiting
NCT04542824 2026-04-08
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2 Active not recruiting